All In Biotech

Drug Trial Radar · NCT03934684

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

101

Actual

Start

Sep 16, 2019

Primary completion

Mar 23, 2023

Study completion Jun 27, 2025

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
May 2, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To characterize safety associated with the use of Kyprolis under the locally approved label.

Conditions

  • Relapsed Refractory Multiple Myeloma

Interventions

  • Drug: Carfilzomib + DexamethasoneDrug

    Drug: Carfilzomib + Dexamethasone * Carfilzomib will be administered as a 30-minute infusion. * Dexamethasone will be taken by mouth or intravenously.

  • Drug: Carfilzomib + Lenalidomide + DexamethasoneDrug

    Drug: Carfilzomib + Lenalidomide + Dexamethasone * Carfilzomib will be administered as a 10 minute infusion. * Lenalidomide will be taken orally. * Dexamethasone will be taken by mouth or intravenously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months
  2. Number of Participants Who Experienced Serious TEAEsTime frame: From the first dose date of any IP until the end of trial; median (min, max) time on trial was 8.7 (0.1, 37.2) months

Locations

17 sites in 1 country. Site status is shown where the registry gives one.

  • Yashoda Hospital

    Hyderabad, Andhra Pradesh, India

  • Apollo Hospital

    Hyderabad, Andhra Pradesh, India

  • M S Ramaiah Memorial Hospital

    Bangalore, Karnataka, India

  • K L E S Dr Prabhakar Kore Hospital and Medical Research Centre

    Belagavi, Karnataka, India

  • Cytecare Cancer Hospitals

    Bengaluru, Karnataka, India

  • Aster Medcity

    Kochi, Kerala, India

  • Government Medical College

    Kozhikode, Kerala, India

  • Tata Memorial Hospital

    Mumbai, Maharashtra, India

  • Mumbai Oncocare Center

    Mumbai, Maharashtra, India

  • Navsanjeevani Hospital

    Nashik, Maharashtra, India

  • Heath Care Group Manavata Cancer Centre

    Nashik, Maharashtra, India

  • Deenanath Mangeshkar Hospital and Research Centre

    Pune, Maharashtra, India

  • Jawaharlal Institute of Postgraduate Medical Education and Research

    Puducherry, Puducherry, India

  • Cancer Institute WIA

    Chennai, Tamil Nadu, India

  • Thangam Cancer Centre

    Namakkal, Tamil Nadu, India

  • Valentis Cancer Hospital

    Meerut, Uttar Pradesh, India

  • Netaji Subhash Chandra Bose Cancer Research Institute

    Kolkata, West Bengal, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.